Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
By G. Livingston, Jonathan Huntley, A. Sommerlad, D. Ames, C. Ballard, Sube Banerjee, Carol Brayne, A. Burns, J. Cohen-Mansfield, C. Cooper and 18 more. The Lancet, 2020
7,984 citations recorded by the source corpus.
Author(s): Livingston, Gill; Huntley, Jonathan; Sommerlad, Andrew; Ames, David; Ballard, Clive; Banerjee, Sube; Brayne, Carol; Burns, Alistair; Cohen-Mansfield, Jiska; Cooper, Claudia; Costafreda, Sergi G; Dias, Amit; Fox, Nick; Gitlin, Laura N; Howard, Robert; Kales, Helen C; Kivimaki, Mika; Larson, Eric B; Ogunniyi, Adesola; Orgeta, Vasiliki; Ritchie, Karen; Rockwood, Kenneth; Sampson, Elizabeth L; Samus, Quincy; Schneider, Lon S; Selbaek, Geir; Teri, Linda; Mukadam, Naaheed
Subfields: Critical Care and Intensive Care Medicine, Geriatrics and Gerontology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/91f71423212ed7f657b7eb1d3181eda86f68158e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Psychiatry and Mental health
Citations in the corpus
- Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 (2022, positive): “13 Addressing these factors through public health interventions is a pathway towards reducing disease prevalence, and future changes in modifiable risk factors might influence the trajectory of trends in age-specific prevalence.”
- Comprehensive Review on Alzheimer’s Disease: Causes and Treatment (2020, background): “At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
- Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024, background): “Smoking was identified as a risk factor for stroke, 22,40 Alzheimer’s disease and other dementias, 41 and multiple sclerosis.”
- The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention (2021, background): “Though AD is indicated by Aβ and tau biomarkers, some cognitively normal individuals having only these biomarkers never develop AD (9), it means that the pre-symptomatic diagnosis is more difficult to obtain.”